3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Endocrinology - Gender: Female -

Spray-on estrogen relieves hot flushes

Endocrinology • • Gender: FemaleJun 02, 08

A form of estrogen, estradiol, sprayed on the skin is a safe, effective, and convenient way for post-menopausal women to relieve hot flushes, a study shows.

Evamist, which is marketed by Ther-Rx Corporation, is the first transdermal estradiol spray to be approved by the US Food and Drug Administration for treating moderate-to-severe menopausal symptoms in healthy women, according to the report in the medical journal Obstetrics & Gynecology.

“This estradiol ‘spray-on-patch’ is a treatment option for women who will benefit from the advantages of transdermal estradiol delivery but are intolerant of or are not inclined to use patches, gels, or emulsions,” write Dr. John E. Buster, from Brown University in Providence, Rhode Island, and colleagues.

The spray solution contains estradiol in ethanol, plus a skin-penetrating agent, and is delivered in a precisely metered dose. It is formulated to be retained beneath the skin’s surface where is slowly released over 24-hours. The spray is applied to the inside of surface of the forearm and dries clear in 1 minute; it can’t be rubbed or washed off and it won’t transfer to other people.

In the study, 454 women with eight or more moderate-to-severe hot flushes per day were randomly assigned to receive one, two, or three sprays of estradiol or an inactive placebo daily.

Compared with the placebo groups, all three estradiol groups showed significant reductions in the frequency and severity of hot flushes.

At 12 weeks, patients in the estradiol groups had eight fewer hot flushes per day on average compared to the start of the study. The reduction in the placebo groups was four to six fewer flushes.

Women given three or two sprays of estradiol showed significant reductions in symptom severity at 4 and 12 weeks compared with women given the placebo. Women treated with one spray of estradiol showed a significant reduction in symptom severity at 5 weeks only.

Adverse events were mild and on par with what has been seen with other transdermal products, the authors note.

The results suggest that this new spray “will be an attractive first choice for transdermal estradiol delivery,” the authors conclude.

SOURCE: Obstetrics & Gynecology, June 2008.

Print Version
comments powered by Disqus

  What’s the life expectancy of patients when they begin treatment for osteoporosis?
  Addressing the needs of young women with disorders of sex development
  Widespread agricultural contaminant impacts fish reproductive behavior
  Study ties breathing problems, asthma to bone loss
  Arkansas to appeal ruling on abortion restriction law
  Supreme Court declines to hear new contraception cases
  Optimism linked to healthier eating among women
  Lactation consultants can boost breastfeeding
  Sexual function dramatically improves in women following bariatric surgery, Penn study finds
  Arkansas governor vetoes bill banning abortions at 20 weeks
  In Vitro Fertilization Less Successful With Alternative Fertility Treatments
  House GOP look to reshape birth control debate


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site